Raymond James sees a rosy outlook ahead for Doximity . The bank upgraded the digital platform for medical professionals to a strong buy from outperform. While it lowered its price target to $65 from $75, that still implies roughly 40% upside from Thursday's close. Analyst Brian Peterson wrote that he was upgrading the stock following a "significant dislocation" after posting its fiscal second-quarter results in May. He added that at 25 times free cash flow, the stock looks "too compelling to ignore." DOCS YTD mountain DOC YTD chart "Doximity has all 3 Ms of a core long-term holding (Moat, Margin, and Management Team), and we think the recent pullback that has shares at a discount to the vertical software group is too great to ignore," he said. "We're also surprised by the company's signifi

See Full Page